Altimmune, Inc. (ALT) · Oct 29, 2026 · New debt
$10M debt draw — $10.0M funded; interest-only period extended to June 1, 2028
Altimmune’s financing update brings in $10 million and extends interest-only payments to June 2028, supporting its Phase 3 development push.
Altimmune is a late-stage biotech advancing pemvidutide into Phase 3 for MASH while also developing it for alcohol-use and alcohol-associated liver disease; its latest reported cash, cash equivalents and investments totaled $519 million as of June 30, 2026.
The financing milestone was achieved and converts available credit into cash. Altimmune drew $10 million from its existing $125 million Hercules facility after meeting the required clinical and financial milestones. This is supportive for the development program, but not a surprise in direction: the facility and milestone-based tranche were disclosed when the loan was amended in November 2025.
The most useful change is funding flexibility, not the $10 million itself. The draw extends the amortization date and interest-only period to June 1, 2028, reducing near-term repayment pressure while Altimmune runs its registrational PERFORMA Phase 3 trial. 〔0〕
| Term | Filing figure | Prior / comparison |
|---|---|---|
| Tranche Three funding (Loan Agreement) | $10.0M | $125.0M total facility |
| Interest-only period (Loan Agreement) | June 1, 2028 | — |
| Minimum Qualified Cash covenant (Loan Agreement) | 60% of outstanding principal | — |
| Tranche facility charge (Loan Agreement) | 1.0% | — |
| End-of-term charge (Loan Agreement) | 6.25% | — |
The trade-off is additional secured debt and a tighter cash restriction. Altimmune must keep qualified cash at least equal to 60% of outstanding term-loan principal, while paying a 1% facility charge and retaining a 6.25% end-of-term charge. 〔1〕 Those costs and constraints matter, but the filing does not suggest a new liquidity problem; rather, it adds debt capacity to an already well-funded clinical-stage program.
Bottom line: This is a modestly constructive financing update: Altimmune met the milestone, added $10 million of non-equity capital, and pushed repayment pressure well beyond the current Phase 3 buildout. It advances the program, though the facility’s fees and cash covenant make it a funding bridge—not a business-model breakthrough.
RESTORE Phase 2 topline data, second half of 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!